<?xml version="1.0" encoding="UTF-8"?>
<p>Eculizumab is a humanized monoclonal IgG antibody that binds to the C5 complement protein, preventing cleavage into C5a and C5b. Blocking the formation of C5b prevents terminal complex C5b-9 or membrane attack complex (MAC) from subsequent formation. In the United States, eculizumab is approved for treating paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome [
 <xref rid="B82-pharmaceuticals-13-00096" ref-type="bibr">82</xref>,
 <xref rid="B83-pharmaceuticals-13-00096" ref-type="bibr">83</xref>].
</p>
